Crynssen Pharma Group Limited
Closed (deSPAC)Health Care · pharmaceutical drug delivery technology and manufacturing
- What it is
- A private company in health care preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Union Acquisition Corp. II (LATN) — closed (despac).
- What you should know
- The deal carries a $185M minimum-cash condition — heavy redemptions can break it.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Transaction is expected to close in the third quarter of 2021" [https://www.nasdaq.com/press-release/procaps-group-a-leading-global-pharmaceutical-technology-and-healthcare-company-based] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Transaction is expected to close in the third quarter of 2021" [https://www.nasdaq.com/press-release/procaps-group-a-leading-global-pharmaceutical-technology-and-healthcare-company-based]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Crynssen Pharma Group Limited is merging with Union Acquisition Corp. II (LATN) currently marked Closed (deSPAC).
| Headline equity value | — |
| PIPE | ≈ $100M · unsourced |
| Minimum cash to close | $185M |
Structure per SEC accession(s) 0001213900-21-045059. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is Crynssen Pharma Group Limited going public?
Crynssen Pharma Group Limited has an approved merger with the SPAC Union Acquisition Corp. II (LATN). Deal status: Closed (deSPAC).
Does Crynssen Pharma Group Limited have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC